Latest Supply Chain Risks News

Almonty Industries has been added to the Russell 1000 and 3000 indexes, marking a key milestone in its market capitalization growth and enhancing its visibility among institutional investors.

Andromeda Metals has started commissioning its High Purity Alumina pilot plant, aiming to produce commercial-grade 4N HPA samples in the second half of 2026 for customer qualification. The pilot plant will also explore value from by-products like amorphous silica and gallium, adding potential upside to the project.

WhiteHawk Limited has forged a strategic alliance with Perth-based Adisyn Services to enhance cyber risk management and compliance solutions tailored for the defence sector, focusing on AUKUS programs and supply chain security.

ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.

Viridis Mining locks in a fixed-price, turnkey contract for critical power infrastructure at its Colossus Rare Earth Project, aligning with the company’s Final Investment Decision and production timelines.

The a2 Milk Company (ASX:A2M) has denied any undisclosed material information following a sharp share price drop and increased trading volumes, attributing market moves to a recent analyst downgrade citing supply chain uncertainties.

Aguia Resources has received official commercialisation approval for its Pampafos phosphate fertiliser project, enabling invoicing and marketing ahead of a targeted sales campaign designed to boost cash flow by mid-2026.

IperionX has commissioned a cutting-edge six-axis SACMI powder metallurgy press in Virginia, tripling its titanium manufacturing capacity and enabling production of complex components for defense and aerospace markets.

Australian Agricultural Company (ASX:AAC) defies North Queensland floods to deliver a 23% jump in operating profit, driven by strong beef pricing and herd valuation gains.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Metcash Limited projects an underlying NPAT between $268 million and $270 million for FY26, buoyed by strong second-half momentum in Hardware & Tools and disciplined cost management driving cash flow and margin resilience.

Yowie Group’s June quarter reveals a revenue decline to $1.93 million, offset by improved operating cash inflows and a successful $516,000 capital raise. The company advances product launches in North America and Australia while undergoing significant board restructuring.